Ziftomenib Approved for Relapsed/Refractory AML With Susceptible NPM1 Mutation
Expert Perspectives · Lyn Brook · 2025-11-19
The FDA has approved the menin inhibitor ziftomenib (Komzifti™, Kura Oncology) for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Why This Approval Matters
This approval adds another targeted menin inhibitor option for patients with relapsed or refractory AML harboring susceptible NPM1 mutations, a population with poor prognosis and limited therapeutic choices. By targeting the menin-NPM1 pathway central to leukemogenesis in this molecular subset, ziftomenib offers a mutation-directed strategy with clinically meaningful remission and transfusion-related benefits.
Breaking Down the KO-MEN-001 Trial
Efficacy was evaluated in the phase 1/2 KO-MEN-001 study (NCT04067336), an open-label, single-arm, multicenter trial that enrolled 112 adults with relapsed or refractory AML and an NPM1 mutation identified by next-generation sequencing or polymerase chain reaction. Patients with NPM1 Type A, B, and D mutations, as well as other NPM1 mutations likely to cause cytoplasmic localization of the NPM1 protein, were included.
Efficacy was evaluated based on the rate of complete remission (CR) plus CR with partial hematologic recovery (CRh), duration of CR+CRh, and conversion from transfusion dependence to transfusion independence. With a median follow-up of 4.2 months, results were as follows:
- CR+CRh rate: 21.4%
- Median duration of CR+CRh: 5.0 months
- CR rate: 17.0%
- CRh rate: 4.5%
There were 66 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline. Among this population, 14 (21.2%) became transfusion-independent during any 56-day post-baseline period. Among the 46 patients who were independent of both RBC and platelet transfusions at baseline, 12 (26.1%) remained transfusion-independent during at least one 56-day post-baseline period.
Managing Adverse Events
The prescribing information for ziftomenib includes warnings and precautions for differentiation syndrome, QTc interval prolongation, and embryo-fetal toxicity.
Dosing and Administration
The recommended dose of ziftomenib is 600 mg taken orally, once daily, continued until disease progression or unacceptable toxicity.